Tyrosine kinase inhibitors with antiangiogenic properties for the treatment of non-small cell lung cancer
Published 2010 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Tyrosine kinase inhibitors with antiangiogenic properties for the treatment of non-small cell lung cancer
Authors
Keywords
-
Journal
EXPERT OPINION ON INVESTIGATIONAL DRUGS
Volume 20, Issue 1, Pages 61-74
Publisher
Informa Healthcare
Online
2010-12-11
DOI
10.1517/13543784.2011.541153
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Synergistic antitumor effect of TRAIL in combination with sunitinib in vitro and in vivo
- (2010) Wanjing Ding et al. CANCER LETTERS
- Sunitinib Acts Primarily on Tumor Endothelium rather than Tumor Cells to Inhibit the Growth of Renal Cell Carcinoma
- (2010) D. Huang et al. CANCER RESEARCH
- Phase I Open-Label Study of Continuous Treatment with BIBF 1120, a Triple Angiokinase Inhibitor, and Pemetrexed in Pretreated Non-Small Cell Lung Cancer Patients
- (2010) P. M. Ellis et al. CLINICAL CANCER RESEARCH
- Phase III Study of Carboplatin and Paclitaxel Alone or With Sorafenib in Advanced Non–Small-Cell Lung Cancer
- (2010) Giorgio Scagliotti et al. JOURNAL OF CLINICAL ONCOLOGY
- Safety and Efficacy of Combining Sunitinib with Bevacizumab + Paclitaxel/Carboplatin in Non-small Cell Lung Cancer
- (2010) Mark A. Socinski et al. Journal of Thoracic Oncology
- Sunitinib Induces Apoptosis and Growth Arrest of Medulloblastoma Tumor Cells by Inhibiting STAT3 and AKT Signaling Pathways
- (2010) F. Yang et al. MOLECULAR CANCER RESEARCH
- Targeted therapy for nonsmall cell lung cancer: focusing on angiogenesis, the epidermal growth factor receptor and multikinase inhibitors
- (2009) Elias A. Kotteas et al. ANTI-CANCER DRUGS
- The -271 G>A polymorphism of kinase insert domain-containing receptor gene regulates its transcription level in patients with non-small cell lung cancer
- (2009) She-Juan An et al. BMC CANCER
- Phase II study of continuous daily sunitinib dosing in patients with previously treated advanced non-small cell lung cancer
- (2009) S Novello et al. BRITISH JOURNAL OF CANCER
- Identification of TNF-α and MMP-9 as potential baseline predictive serum markers of sunitinib activity in patients with renal cell carcinoma using a human cytokine array
- (2009) J L Perez-Gracia et al. BRITISH JOURNAL OF CANCER
- Accelerated Metastasis after Short-Term Treatment with a Potent Inhibitor of Tumor Angiogenesis
- (2009) John M.L. Ebos et al. CANCER CELL
- Antiangiogenic Therapy Elicits Malignant Progression of Tumors to Increased Local Invasion and Distant Metastasis
- (2009) Marta Pàez-Ribes et al. CANCER CELL
- FMS-Like Tyrosine Kinase 3-Internal Tandem Duplication Tyrosine Kinase Inhibitors Display a Nonoverlapping Profile of Resistance Mutations In vitro
- (2009) N. von Bubnoff et al. CANCER RESEARCH
- A “Vascular Normalization Index” as Potential Mechanistic Biomarker to Predict Survival after a Single Dose of Cediranib in Recurrent Glioblastoma Patients
- (2009) A. Gregory Sorensen et al. CANCER RESEARCH
- Mechanisms of Sunitinib Resistance in Gastrointestinal Stromal Tumors Harboring KITAY502-3ins Mutation: An In vitro Mutagenesis Screen for Drug Resistance
- (2009) T. Guo et al. CLINICAL CANCER RESEARCH
- Circulating Levels of Soluble KIT Serve as a Biomarker for Clinical Outcome in Gastrointestinal Stromal Tumor Patients Receiving Sunitinib following Imatinib Failure
- (2009) S. E. DePrimo et al. CLINICAL CANCER RESEARCH
- Phase 1b Study of Motesanib, an Oral Angiogenesis Inhibitor, in Combination with Carboplatin/Paclitaxel and/or Panitumumab for the Treatment of Advanced Non-Small Cell Lung Cancer
- (2009) G. R. Blumenschein et al. CLINICAL CANCER RESEARCH
- Tumor and Host-Mediated Pathways of Resistance and Disease Progression in Response to Antiangiogenic Therapy
- (2009) J. M. L. Ebos et al. CLINICAL CANCER RESEARCH
- Phase I Trial of Pazopanib in Patients with Advanced Cancer
- (2009) H. I. Hurwitz et al. CLINICAL CANCER RESEARCH
- Receptor Tryosine Kinase Inhibitors as Potent Weapons in War Against Cancers
- (2009) P. Sharma et al. CURRENT PHARMACEUTICAL DESIGN
- Sunitinib-resistant gastrointestinal stromal tumors harbor cis-mutations in the activation loop of the KIT gene
- (2009) Toshirou Nishida et al. International Journal of Clinical Oncology
- Randomized Phase II Trial of First-Line Treatment With Sorafenib Versus Interferon Alfa-2a in Patients With Metastatic Renal Cell Carcinoma
- (2009) Bernard Escudier et al. JOURNAL OF CLINICAL ONCOLOGY
- Efficacy and Safety of Axitinib in Patients With Advanced Non–Small-Cell Lung Cancer: Results From a Phase II Study
- (2009) Joan H. Schiller et al. JOURNAL OF CLINICAL ONCOLOGY
- Vandetanib Versus Gefitinib in Patients With Advanced Non–Small-Cell Lung Cancer: Results From a Two-Part, Double-Blind, Randomized Phase II Study
- (2009) Ronald B. Natale et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II, Multicenter, Uncontrolled Trial of Single-Agent Sorafenib in Patients With Relapsed or Refractory, Advanced Non–Small-Cell Lung Cancer
- (2009) George R. Blumenschein et al. JOURNAL OF CLINICAL ONCOLOGY
- Pazopanib, a Multikinase Angiogenesis Inhibitor, in Patients With Relapsed or Refractory Advanced Soft Tissue Sarcoma: A Phase II Study From the European Organisation for Research and Treatment of Cancer–Soft Tissue and Bone Sarcoma Group (EORTC Study 62043)
- (2009) Stefan Sleijfer et al. JOURNAL OF CLINICAL ONCOLOGY
- Adverse effects of anticancer agents that target the VEGF pathway
- (2009) Helen X. Chen et al. Nature Reviews Clinical Oncology
- KIT kinase mutants show unique mechanisms of drug resistance to imatinib and sunitinib in gastrointestinal stromal tumor patients
- (2009) K. S. Gajiwala et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- BIBF 1120: Triple Angiokinase Inhibitor with Sustained Receptor Blockade and Good Antitumor Efficacy
- (2008) F. Hilberg et al. CANCER RESEARCH
- Nonclinical Antiangiogenesis and Antitumor Activities of Axitinib (AG-013736), an Oral, Potent, and Selective Inhibitor of Vascular Endothelial Growth Factor Receptor Tyrosine Kinases 1, 2, 3
- (2008) D. D. Hu-Lowe et al. CLINICAL CANCER RESEARCH
- Can Tyrosine Kinase Inhibitors be Discontinued in Patients with Metastatic Renal Cell Carcinoma and a Complete Response to Treatment? A Multicentre, Retrospective Analysis
- (2008) Manfred Johannsen et al. EUROPEAN UROLOGY
- Pazopanib, a potent orally administered small-molecule multitargeted tyrosine kinase inhibitor for renal cell carcinoma
- (2008) Guru Sonpavde et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Axitinib Is an Active Treatment for All Histologic Subtypes of Advanced Thyroid Cancer: Results From a Phase II Study
- (2008) Ezra E.W. Cohen et al. JOURNAL OF CLINICAL ONCOLOGY
- Combination Targeted Therapy With Sorafenib and Bevacizumab Results in Enhanced Toxicity and Antitumor Activity
- (2008) Nilofer S. Azad et al. JOURNAL OF CLINICAL ONCOLOGY
- Antitumor Activity and Biomarker Analysis of Sunitinib in Patients With Bevacizumab-Refractory Metastatic Renal Cell Carcinoma
- (2008) Brian I. Rini et al. JOURNAL OF CLINICAL ONCOLOGY
- Multicenter, Phase II Trial of Sunitinib in Previously Treated, Advanced Non–Small-Cell Lung Cancer
- (2008) Mark A. Socinski et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Study of Sunitinib Malate, an Oral Multitargeted Tyrosine Kinase Inhibitor, in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane
- (2008) Harold J. Burstein et al. JOURNAL OF CLINICAL ONCOLOGY
- Primary and Secondary Kinase Genotypes Correlate With the Biological and Clinical Activity of Sunitinib in Imatinib-Resistant Gastrointestinal Stromal Tumor
- (2008) Michael C. Heinrich et al. JOURNAL OF CLINICAL ONCOLOGY
- Discovery of 5-[[4-[(2,3-Dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methyl-benzenesulfonamide (Pazopanib), a Novel and Potent Vascular Endothelial Growth Factor Receptor Inhibitor†
- (2008) Philip A. Harris et al. JOURNAL OF MEDICINAL CHEMISTRY
- R Regulation of tumor angiogenesis and metastasis by FGF and PDGF signaling pathways
- (2008) Yihai Cao et al. JOURNAL OF MOLECULAR MEDICINE-JMM
- Prognostic Impact of Platelet-Derived Growth Factors in Non-small Cell Lung Cancer Tumor and Stromal Cells
- (2008) Tom Donnem et al. Journal of Thoracic Oncology
- Efficacy of gemcitabine plus axitinib compared with gemcitabine alone in patients with advanced pancreatic cancer: an open-label randomised phase II study
- (2008) Jean-Philippe Spano et al. LANCET
- Sorafenib in Advanced Hepatocellular Carcinoma
- (2008) Josep M. Llovet et al. NEW ENGLAND JOURNAL OF MEDICINE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started